Skin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease

被引:11
|
作者
Ueceyler, Nurcan [1 ,3 ]
Schroeter, Nils [1 ,3 ]
Kafke, Waldemar [1 ,3 ]
Kramer, Daniela [1 ,3 ]
Wanner, Christoph [2 ,3 ]
Weidemann, Frank [2 ,3 ,4 ]
Sommer, Claudia [1 ,3 ]
机构
[1] Univ Wurzburg, Dept Neurol, Wurzburg, Germany
[2] Univ Wurzburg, Dept Internal Med, Wurzburg, Germany
[3] Univ Wurzburg, Wurzburg Fabry Ctr Interdisciplinary Therapy FAZI, Wurzburg, Germany
[4] Katharinen Hosp Unna, Innere Klin 2, Obere Husemannstr 2, D-59423 Unna, Germany
来源
PLOS ONE | 2016年 / 11卷 / 11期
关键词
ENZYME REPLACEMENT THERAPY; PAIN SYMPTOM INVENTORY; SMALL FIBER NEUROPATHY; AGALSIDASE-BETA; DIAGNOSIS; NEPHROPATHY; BIOPSIES; EFFICACY; SAFETY; TRIAL;
D O I
10.1371/journal.pone.0166484
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The X-chromosomally linked life-limiting Fabry disease (FD) is associated with deposits of the sphingolipid globotriaosylceramide 3 (Gb3) in various tissues. Skin is easily accessible and may be used as an additional diagnostic and follow-up medium. Our aims were to visualize skin Gb3 deposits in FD patients applying immunofluorescence and to determine if cutaneous Gb3 load correlates with disease severity. Methods At our Fabry Center for Interdisciplinary Therapy we enrolled 84 patients with FD and 27 healthy controls. All subjects underwent 5-mm skin punch biopsy at the lateral lower leg and the back. Skin samples were processed for immunohistochemistry using antibodies against CD77 (i.e. Gb3). Cutaneous Gb3 deposition was quantified in a blinded manner and correlated to clinical data. Results We found that Gb3 load was higher in distal skin of male FD patients compared to healthy controls (p<0.05). Men (p<0.01) and women (p<0.05) with a classic FD phenotype had higher distal skin Gb3 load than healthy controls. Men with advanced disease as reflected by impaired renal function, and men and women with small fiber neuropathy had more Gb3 deposits in distal skin samples than males with normal renal function (p<0.05) and without small fiber neuropathy. Gb3 deposits were not different between patients with and without enzyme replacement therapy. Conclusions Immunofluorescence on minimally invasive skin punch biopsies may be useful as a tool for assessment and follow-up in FD patients.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Elevation of urinary globotriaosylceramide (GL3) in infants with Fabry disease
    Chien, Yin-Hsiu
    Olivova, Petra
    Zhang, Xiaokui Kate
    Chiang, Shu-Chuan
    Lee, Ni-Chung
    Keutzer, Joan
    Hwu, Wuh-Liang
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (01) : 57 - 60
  • [2] Is globotriaosylceramide a useful biomarker in Fabry disease?
    Young, E
    Mills, K
    Morris, P
    Vellodi, A
    Lee, P
    Waldek, S
    Winchester, B
    ACTA PAEDIATRICA, 2005, 94 : 51 - 54
  • [3] Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues
    Tondel, Camilla
    Thurberg, Beth L.
    DasMahapatra, Pronabesh
    Lyn, Nicole
    Maski, Manish
    Batista, Julie L.
    George, Kelly
    Patel, Hiren
    Hariri, Ali
    MOLECULAR GENETICS AND METABOLISM, 2022, 137 (04) : 328 - 341
  • [4] Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease
    Taguchi, Atsumi
    Ishii, Satoshi
    Mikame, Mariko
    Maruyama, Hiroki
    MOLECULAR GENETICS AND METABOLISM REPORTS, 2023, 34
  • [5] Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease
    Moura, Alana Pimentel
    Hammerschmidt, Tatiane
    Deon, Marion
    Giugliani, Roberto
    Vargas, Carmen Regla
    CLINICA CHIMICA ACTA, 2018, 478 : 62 - 67
  • [6] Determination of globotriaosylceramide analogs in the organs of a mouse model of Fabry disease
    Ishii, Satoshi
    Taguchi, Atsumi
    Okino, Nozomu
    Ito, Makoto
    Maruyama, Hiroki
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2020, 295 (17) : 5577 - 5587
  • [7] Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease
    Apelland, Turid
    Gude, Einar
    Strom, Erik H.
    Gullestad, Lars
    Eiklid, Kristin L.
    Mansson, Jan-Eric
    Reinholt, Finn P.
    Houge, Gunnar
    Dahl, Christen P.
    Almaas, Vibeke M.
    Heiberg, Arvid
    HEART, 2014, 100 (22) : 1793 - 1798
  • [8] Urinary Total Globotriaosylceramide and Isoforms to Identify Women With Fabry Disease: A Diagnostic Test Study
    Paschke, Eduard
    Fauler, Guenter
    Winkler, Heimo
    Schlagenhauf, Axel
    Plecko, Barbara
    Erwa, Wolfgang
    Breunig, Frank
    Urban, Wolfgang
    Vujkovac, Bojan
    Sunder-Plassmann, Gere
    Kotanko, Peter
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (05) : 673 - 681
  • [9] Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease
    Najafian, Behzad
    Svarstad, Einar
    Bostad, Leif
    Gubler, Marie-Claire
    Tondel, Camilla
    Whitley, Chester
    Mauer, Michael
    KIDNEY INTERNATIONAL, 2011, 79 (06) : 663 - 670
  • [10] A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse
    Shin, Seok-Ho
    Park, Min-Ho
    Byeon, Jin-Ju
    Lee, Byeong Ill
    Park, Yuri
    Ko, Ah-ra
    Seong, Mi-ran
    Lee, Soyeon
    Kim, Mi Ra
    Seo, Jinwook
    Jung, Myung Eun
    Jin, Dong-Kyu
    Shin, Young G.
    PHARMACEUTICS, 2018, 10 (02):